

# HIV SEMI-ANNUAL SURVEILLANCE REPORT

## San Francisco Department of Public Health

### HIV Cases Diagnosed Through December 2023 and Reported Through March 2, 2024

<b>Contents</b>	<b>Page</b>
Surveillance Summary.....	1
Figure 1. Diagnoses of HIV infection, HIV deaths and persons living with HIV by year .....	2
Figure 2. Diagnoses of HIV infection stage 3 (AIDS), AIDS deaths and persons living with AIDS by year .....	2
Figure 3. Continuum of HIV care among persons newly diagnosed with HIV .....	3
Table 1. Diagnoses of HIV infection by age and year of initial HIV diagnosis.....	4
Table 2. Diagnoses of HIV infection stage 3 (AIDS) by age and year of AIDS diagnosis.....	5
Table 3. Diagnoses of HIV infection by gender and year of initial HIV diagnosis .....	6
Table 4. Diagnoses of HIV infection stage 3 (AIDS) by gender and year of AIDS diagnosis...	7
Table 5. Diagnoses of HIV infection by race/ethnicity and year of initial HIV diagnosis.....	8
Table 6. Diagnoses of HIV infection stage 3 (AIDS) by race/ethnicity and year of AIDS diagnosis.....	9
Table 7. Diagnoses of HIV infection by transmission category and year of initial HIV diagnosis.....	10
Table 8. Diagnoses of HIV infection stage 3 (AIDS) by transmission category and year of AIDS diagnosis.....	11
Table 9. Diagnoses of HIV infection, HIV deaths and persons living with HIV by year .....	12
Table 10. Diagnoses of HIV infection stage 3 (AIDS), AIDS deaths and persons living with AIDS by year .....	13
Table 11. Persons living with HIV infection by age, gender and race/ethnicity.....	14
Table 12. Persons living with HIV infection by transmission category, gender and race/ethnicity.....	15

The HIV Surveillance Report is published semi-annually by the  
San Francisco Department of Public Health, Population Health Division  
Applied Research, Community Health Epidemiology, and Surveillance Branch (ARCHES)  
25 Van Ness Avenue, Suite 500, San Francisco, CA 94102; Phone (628) 217-6336, FAX (415) 431-0353

Director of Health: Grant Colfax, MD  
Director of Population Health Division: Susan Phillip, MD, MPH  
Acting Manager HIV Epidemiology Unit: Sharon Pipkin, MPH

***The HIV Surveillance Report is accessible via internet:  
<https://www.sf.gov/resource/2024/hiv-epidemiology-unit-reports>***

# HIV SURVEILLANCE SUMMARY

## San Francisco<sup>a</sup> (as of 12/31/2023)

Persons living with HIV infection (all disease stages)	15,543
Persons living with HIV infection ever classified as stage 3 (AIDS)	8,518
Diagnoses of HIV infection, 2023	132
Deaths of persons diagnosed with HIV infection, 2023	191
Deaths of persons diagnosed with HIV infection ever classified as stage 3 (AIDS), 2023	148

## California<sup>b</sup> (as of 12/31/2022)

Persons living with HIV infection (all disease stages)	142,772
Persons living with HIV infection ever classified as stage 3 (AIDS) <sup>c</sup>	64,486
Diagnoses of HIV infection, 2022	4,882
Deaths of persons diagnosed with HIV infection, 2022	2,169
Deaths of persons diagnosed with HIV infection ever classified as stage 3 (AIDS), 2021 <sup>d</sup>	1,640

## United States<sup>e</sup> (as of 12/31/2021)

Persons living with HIV infection (all disease stages)	1,088,769
Persons living with HIV infection ever classified as stage 3 (AIDS)	NA
Diagnoses of HIV infection, 2021	36,189
Deaths of persons diagnosed with HIV infection, 2021	19,986
Deaths of persons diagnosed with HIV infection ever classified as stage 3 (AIDS), 2021 <sup>d</sup>	14,993

<sup>a</sup> Residents of San Francisco at time of HIV or AIDS diagnosis.


<sup>b</sup> California HIV Surveillance Report 2022. [https://www.cdph.ca.gov/Programs/CID/DOA/Pages/OA\\_case\\_surveillance\\_reports.aspx](https://www.cdph.ca.gov/Programs/CID/DOA/Pages/OA_case_surveillance_reports.aspx). Released 02/09/2024. Accessed 03/07/2024.

<sup>c</sup> Supplemental Tables to the California HIV Surveillance Report — 2022. [https://www.cdph.ca.gov/Programs/CID/DOA/Pages/OA\\_case\\_surveillance\\_reports.aspx](https://www.cdph.ca.gov/Programs/CID/DOA/Pages/OA_case_surveillance_reports.aspx). Released 02/27/2024. Accessed 03/07/2024.

<sup>d</sup> CDC. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2021. HIV Surveillance Supplemental Report 2023;28(No. 4). (Table 7f) <http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html>. Published May 2023. Accessed 03/07/2024.


<sup>e</sup> CDC. HIV Surveillance Report, Diagnoses of HIV Infection in the United States and Dependent Areas, 2021; vol. 34. (Table 1b, 11b, 15b). <http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html>. Published May 23, 2023. Accessed 03/07/2024.

**Figure 1. Diagnoses of HIV infection, HIV deaths and persons living with HIV by year, San Francisco, 2002-2023\***




\* Reporting for recent years is incomplete. See Table 9 for actual numbers per year.

**Figure 2. Diagnoses of HIV infection stage 3 (AIDS), AIDS deaths and persons living with AIDS by year, San Francisco, 1980-2023†**



† Reporting for recent years is incomplete. See Table 10 for actual numbers per year.

**Figure 3. Continuum of HIV care among persons newly diagnosed with HIV, San Francisco**



### Month/Year of HIV Diagnosis

The month and year of HIV diagnosis are determined based on the earliest date of a positive HIV antibody/antigen test, detectable viral load, or physician-documented diagnosis in absence of sufficient laboratory evidence, and do not consider patient self-report of a positive HIV test. For other parts of this report that assess trends in HIV diagnoses, the year of initial HIV diagnosis takes into account self-report of HIV infection. Therefore, the numbers shown in Figure 3 may differ from other data presented in this report.

### Linkage to Care

Linkage to care is measured by the documentation of CD4, viral load or genotype tests performed within one month of diagnosis.

### Viral Suppression

Viral suppression is measured by a viral load less than 200 copies/mL performed within six months of diagnosis.

## HIV Semi-Annual Surveillance Report Cases Diagnosed as of 12/31/2023 and Reported as of 03/02/2024

Table 1. Diagnoses of HIV infection by age and year of initial HIV diagnosis (1), San Francisco, 2012-2023

Age at initial HIV diagnosis (years)	Year of initial HIV diagnosis					
	2012 No. (%)	2013 No. (%)	2014 No. (%)	2015 No. (%)	2016 No. (%)	2017 No. (%)
0 - 12	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)
13 - 17	0 ( 0.0)	2 ( 0.5)	1 ( 0.3)	3 ( 1.0)	1 ( 0.4)	3 ( 1.2)
18 - 24	66 (13.7)	65 (15.9)	43 (13.2)	43 (13.9)	45 (17.8)	28 (11.1)
25 - 29	80 (16.6)	85 (20.8)	59 (18.1)	78 (25.2)	54 (21.3)	45 (17.9)
30 - 39	145 (30.0)	114 (27.9)	96 (29.4)	90 (29.0)	78 (30.8)	87 (34.5)
40 - 49	134 (27.7)	96 (23.5)	74 (22.7)	65 (21.0)	38 (15.0)	52 (20.6)
50 - 59	46 ( 9.5)	34 ( 8.3)	40 (12.3)	18 ( 5.8)	26 (10.3)	26 (10.3)
60 +	12 ( 2.5)	13 ( 3.2)	13 ( 4.0)	13 ( 4.2)	11 ( 4.3)	11 ( 4.4)
<b>Total</b>	<b>483 ( 100)</b>	<b>409 ( 100)</b>	<b>326 ( 100)</b>	<b>310 ( 100)</b>	<b>253 ( 100)</b>	<b>252 ( 100)</b>

Age at initial HIV diagnosis (years)	Year of initial HIV diagnosis					
	2018 No. (%)	2019 No. (%)	2020 No. (%)	2021 No. (%)	2022 No. (%)	2023 No. (%)
0 - 12	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)
13 - 17	1 ( 0.5)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)
18 - 24	36 (16.4)	20 (10.9)	22 (14.5)	14 ( 8.2)	19 (11.4)	20 (15.2)
25 - 29	44 (20.0)	30 (16.4)	26 (17.1)	34 (19.9)	36 (21.6)	16 (12.1)
30 - 39	70 (31.8)	67 (36.6)	48 (31.6)	59 (34.5)	49 (29.3)	47 (35.6)
40 - 49	43 (19.5)	30 (16.4)	27 (17.8)	34 (19.9)	37 (22.2)	27 (20.5)
50 - 59	16 ( 7.3)	21 (11.5)	23 (15.1)	23 (13.5)	17 (10.2)	13 ( 9.8)
60 +	10 ( 4.5)	15 ( 8.2)	6 ( 3.9)	7 ( 4.1)	9 ( 5.4)	9 ( 6.8)
<b>Total</b>	<b>220 ( 100)</b>	<b>183 ( 100)</b>	<b>152 ( 100)</b>	<b>171 ( 100)</b>	<b>167 ( 100)</b>	<b>132 ( 100)</b>

(1) Includes persons diagnosed with HIV infection regardless of disease stage. The initial year of HIV diagnosis was determined based on the earliest date of positive HIV antibody test, positive HIV antigen/antibody combination test, detectable viral load, physician-documented diagnosis in absence of sufficient laboratory evidence, or patient self-report of a positive HIV test. Data in recent years are incomplete due to delays in case reporting.

## HIV Semi-Annual Surveillance Report Cases Diagnosed as of 12/31/2023 and Reported as of 03/02/2024

Table 2. Diagnoses of HIV infection stage 3 (AIDS) by age and year of AIDS diagnosis (1), San Francisco, 2012-2023

Age at AIDS diagnosis (years)	Year of AIDS diagnosis					
	2012 No. (%)	2013 No. (%)	2014 No. (%)	2015 No. (%)	2016 No. (%)	2017 No. (%)
0 - 12	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)
13 - 17	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	1 ( 0.8)
18 - 24	11 ( 4.5)	10 ( 5.3)	6 ( 4.3)	4 ( 3.2)	2 ( 2.1)	1 ( 0.8)
25 - 29	26 (10.7)	17 ( 9.1)	13 ( 9.4)	9 ( 7.2)	8 ( 8.2)	16 (12.1)
30 - 39	60 (24.7)	43 (23.0)	41 (29.5)	35 (28.0)	27 (27.8)	32 (24.2)
40 - 49	83 (34.2)	58 (31.0)	40 (28.8)	35 (28.0)	23 (23.7)	41 (31.1)
50 - 59	43 (17.7)	38 (20.3)	26 (18.7)	28 (22.4)	19 (19.6)	15 (11.4)
60 +	20 ( 8.2)	21 (11.2)	13 ( 9.4)	14 (11.2)	18 (18.6)	26 (19.7)
<b>Total</b>	<b>243 ( 100)</b>	<b>187 ( 100)</b>	<b>139 ( 100)</b>	<b>125 (100)</b>	<b>97 ( 100)</b>	<b>132 ( 100)</b>

Age at AIDS diagnosis (years)	Year of AIDS diagnosis					
	2018 No. (%)	2019 No. (%)	2020 No. (%)	2021 No. (%)	2022 No. (%)	2023 No. (%)
0 - 12	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)
13 - 17	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)
18 - 24	3 ( 2.6)	2 ( 1.8)	2 ( 2.3)	2 ( 2.2)	3 ( 4.2)	2 ( 2.2)
25 - 29	12 (10.4)	9 ( 8.1)	8 ( 9.1)	11 (12.4)	7 ( 9.7)	6 ( 6.5)
30 - 39	32 (27.8)	32 (28.8)	27 (30.7)	18 (20.2)	20 (27.8)	24 (26.1)
40 - 49	21 (18.3)	26 (23.4)	17 (19.3)	22 (24.7)	20 (27.8)	17 (18.5)
50 - 59	26 (22.6)	24 (21.6)	19 (21.6)	24 (27.0)	14 (19.4)	27 (29.3)
60 +	21 (18.3)	18 (16.2)	15 (17.0)	12 (13.5)	8 (11.1)	16 (17.4)
<b>Total</b>	<b>115 ( 100)</b>	<b>111 ( 100)</b>	<b>88 ( 100)</b>	<b>89 ( 100)</b>	<b>72 ( 100)</b>	<b>92 ( 100)</b>

(1) Data in recent years are incomplete due to delays in case reporting.

## HIV Semi-Annual Surveillance Report Cases Diagnosed as of 12/31/2023 and Reported as of 03/02/2024

**Table 3. Diagnoses of HIV infection by gender and year of initial HIV diagnosis (1), San Francisco, 2012-2023**

Gender (2)	Year of initial HIV diagnosis					
	2012 No. (%)	2013 No. (%)	2014 No. (%)	2015 No. (%)	2016 No. (%)	2017 No. (%)
Cis Men	441 (91.3)	374 (91.4)	301 (92.3)	273 (88.1)	215 (85.0)	219 (86.9)
Cis Women	28 ( 5.8)	22 ( 5.4)	13 ( 4.0)	29 ( 9.4)	25 ( 9.9)	27 (10.7)
Trans Women	14 ( 2.9)	13 ( 3.2)	12 ( 3.7)	8 ( 2.6)	12 ( 4.7)	6 ( 2.4)
<b>Total</b>	<b>483 ( 100)</b>	<b>409 ( 100)</b>	<b>326 ( 100)</b>	<b>310 ( 100)</b>	<b>253 ( 100)</b>	<b>252 ( 100)</b>

Gender (2)	Year of initial HIV diagnosis					
	2018 No. (%)	2019 No. (%)	2020 No. (%)	2021 No. (%)	2022 No. (%)	2023 No. (%)
Cis Men	192 (87.3)	151 (82.5)	123 (80.9)	133 (77.8)	142 (85.0)	106 (80.3)
Cis Women	17 ( 7.7)	16 ( 8.7)	17 (11.2)	22 (12.9)	14 ( 8.4)	13 ( 9.8)
Trans Women	10 ( 4.5)	14 ( 7.7)	11 ( 7.2)	15 ( 8.8)	10 ( 6.0)	11 ( 8.3)
<b>Total</b>	<b>220 ( 100)</b>	<b>183 ( 100)</b>	<b>152 ( 100)</b>	<b>171 ( 100)</b>	<b>167 ( 100)</b>	<b>132 ( 100)</b>

(1) Includes persons diagnosed with HIV infection regardless of disease stage. The initial year of HIV diagnosis was determined based on the earliest date of positive HIV antibody test, positive HIV antigen/antibody combination test, detectable viral load, physician-documented diagnosis in absence of sufficient laboratory evidence, or patient self-report of a positive HIV test. Data in recent years are incomplete due to delays in case reporting.

(2) Data on trans men are not released separately due to small numbers.

## HIV Semi-Annual Surveillance Report Cases Diagnosed as of 12/31/2023 and Reported as of 03/02/2024

Table 4. Diagnoses of HIV infection stage 3 (AIDS) by gender and year of AIDS diagnosis (1), San Francisco, 2012-2023

Gender (2)	Year of AIDS diagnosis					
	2012 No. (%)	2013 No. (%)	2014 No. (%)	2015 No. (%)	2016 No. (%)	2017 No. (%)
Cis Men	210 (86.4)	164 (87.7)	125 (89.9)	98 (78.4)	82 (84.5)	104 (78.8)
Cis Women	24 (9.9)	17 (9.1)	7 (5.0)	19 (15.2)	11 (11.3)	22 (16.7)
Trans Women	9 (3.7)	6 (3.2)	7 (5.0)	8 (6.4)	3 (3.1)	6 (4.5)
<b>Total</b>	<b>243 (100)</b>	<b>187 (100)</b>	<b>139 (100)</b>	<b>125 (100)</b>	<b>97 (100)</b>	<b>132 (100)</b>

Gender (2)	Year of AIDS diagnosis					
	2018 No. (%)	2019 No. (%)	2020 No. (%)	2021 No. (%)	2022 No. (%)	2023 No. (%)
Cis Men	100 (87.0)	97 (87.4)	72 (81.8)	69 (77.5)	64 (88.9)	79 (85.9)
Cis Women	12 (10.4)	7 (6.3)	10 (11.4)	11 (12.4)	7 (9.7)	9 (9.8)
Trans Women	3 (2.6)	7 (6.3)	6 (6.8)	8 (9.0)	1 (1.4)	4 (4.3)
<b>Total</b>	<b>115 (100)</b>	<b>111 (100)</b>	<b>88 (100)</b>	<b>89 (100)</b>	<b>72 (100)</b>	<b>92 (100)</b>

(1) Data in recent years are incomplete due to delays in case reporting.

(2) Data on trans men are not released separately due to small numbers.



## HIV Semi-Annual Surveillance Report Cases Diagnosed as of 12/31/2023 and Reported as of 03/02/2024

Table 5. Diagnoses of HIV infection by race/ethnicity and year of initial HIV diagnosis (1), San Francisco, 2012-2023

Race/ethnicity	Year of initial HIV diagnosis					
	2012 No. (%)	2013 No. (%)	2014 No. (%)	2015 No. (%)	2016 No. (%)	2017 No. (%)
White	230 (47.6)	181 (44.3)	133 (40.8)	122 (39.4)	91 (36.0)	83 (32.9)
Black/African American	54 (11.2)	48 (11.7)	33 (10.1)	44 (14.2)	32 (12.6)	42 (16.7)
Latinx	119 (24.6)	115 (28.1)	98 (30.1)	85 (27.4)	81 (32.0)	79 (31.3)
Asian/Pacific Islander/ Native American	58 (12.0)	50 (12.2)	46 (14.1)	40 (12.9)	42 (16.6)	35 (13.9)
Multiple races	21 ( 4.3)	14 ( 3.4)	16 ( 4.9)	18 ( 5.8)	7 ( 2.8)	13 ( 5.2)
<b>Total (2)</b>	<b>483 ( 100)</b>	<b>409 ( 100)</b>	<b>326 ( 100)</b>	<b>310 ( 100)</b>	<b>253 ( 100)</b>	<b>252 ( 100)</b>

Race/ethnicity	Year of initial HIV diagnosis					
	2018 No. (%)	2019 No. (%)	2020 No. (%)	2021 No. (%)	2022 No. (%)	2023 No. (%)
White	61 (27.7)	58 (31.7)	40 (26.3)	55 (32.2)	46 (27.5)	48 (36.4)
Black/African American	40 (18.2)	29 (15.8)	28 (18.4)	26 (15.2)	25 (15.0)	25 (18.9)
Latinx	90 (40.9)	66 (36.1)	64 (42.1)	63 (36.8)	74 (44.3)	40 (30.3)
Asian/Pacific Islander/ Native American	23 (10.5)	25 (13.7)	18 (11.8)	24 (14.0)	20 (12.0)	19 (14.4)
Multiple races	6 ( 2.7)	5 ( 2.7)	2 ( 1.3)	3 ( 1.8)	2 ( 1.2)	0 ( 0.0)
<b>Total (2)</b>	<b>220 ( 100)</b>	<b>183 ( 100)</b>	<b>152 ( 100)</b>	<b>171 ( 100)</b>	<b>167 ( 100)</b>	<b>132 ( 100)</b>

(1) Includes persons diagnosed with HIV infection regardless of disease stage. The initial year of HIV diagnosis was determined based on the earliest date of positive HIV antibody test, positive HIV antigen/antibody combination test, detectable viral load, physician-documented diagnosis in absence of sufficient laboratory evidence, or patient self-report of a positive HIV test. Data in recent years are incomplete due to delays in case reporting.

(2) Total includes persons with unknown race.

## HIV Semi-Annual Surveillance Report Cases Diagnosed as of 12/31/2023 and Reported as of 03/02/2024

Table 6. Diagnoses of HIV infection stage 3 (AIDS) by race/ethnicity and year of AIDS diagnosis (1), San Francisco, 2012-2023

Race/ethnicity	Year of AIDS diagnosis					
	2012 No. (%)	2013 No. (%)	2014 No. (%)	2015 No. (%)	2016 No. (%)	2017 No. (%)
White	119 (49.0)	90 (48.1)	52 (37.4)	60 (48.0)	42 (43.3)	52 (39.4)
Black/African American	40 (16.5)	30 (16.0)	28 (20.1)	19 (15.2)	15 (15.5)	26 (19.7)
Latinx	55 (22.6)	38 (20.3)	32 (23.0)	32 (25.6)	21 (21.6)	35 (26.5)
Asian/Pacific Islander/ Native American	14 ( 5.8)	17 ( 9.1)	16 (11.5)	5 ( 4.0)	12 (12.4)	14 (10.6)
Multiple races	15 ( 6.2)	12 ( 6.4)	11 ( 7.9)	9 ( 7.2)	7 ( 7.2)	5 ( 3.8)
<b>Total (2)</b>	<b>243 ( 100)</b>	<b>187 ( 100)</b>	<b>139 ( 100)</b>	<b>125 ( 100)</b>	<b>97 ( 100)</b>	<b>132 ( 100)</b>

Race/ethnicity	Year of AIDS diagnosis					
	2018 No. (%)	2019 No. (%)	2020 No. (%)	2021 No. (%)	2022 No. (%)	2023 No. (%)
White	36 (31.3)	42 (37.8)	38 (43.2)	29 (32.6)	28 (38.9)	33 (35.9)
Black/African American	18 (15.7)	24 (21.6)	17 (19.3)	15 (16.9)	10 (13.9)	14 (15.2)
Latinx	41 (35.7)	21 (18.9)	22 (25.0)	30 (33.7)	23 (31.9)	30 (32.6)
Asian/Pacific Islander/ Native American	10 ( 8.7)	15 (13.5)	8 ( 9.1)	10 (11.2)	9 (12.5)	9 ( 9.8)
Multiple races	10 ( 8.7)	9 ( 8.1)	3 ( 3.4)	5 ( 5.6)	2 ( 2.8)	6 ( 6.5)
<b>Total (2)</b>	<b>115 ( 100)</b>	<b>111 ( 100)</b>	<b>88 ( 100)</b>	<b>89 ( 100)</b>	<b>72 ( 100)</b>	<b>92 ( 100)</b>

(1) Data in recent years are incomplete due to delays in case reporting.

(2) Total includes persons with unknown race.

## HIV Semi-Annual Surveillance Report Cases Diagnosed as of 12/31/2023 and Reported as of 03/02/2024

**Table 7. Diagnoses of HIV infection by transmission category and year of initial HIV diagnosis (1), San Francisco, 2012-2023**

Transmission category (2)	Year of initial HIV diagnosis					
	2012 No. (%)	2013 No. (%)	2014 No. (%)	2015 No. (%)	2016 No. (%)	2017 No. (%)
Men who have sex with men (MSM)	369 (76.4)	316 (77.3)	249 (76.4)	237 (76.5)	180 (71.1)	156 (61.9)
People who inject drugs (PWID)	22 ( 4.6)	21 ( 5.1)	24 ( 7.4)	17 ( 5.5)	22 ( 8.7)	26 (10.3)
MSM-PWID	55 (11.4)	48 (11.7)	42 (12.9)	28 ( 9.0)	27 (10.7)	35 (13.9)
Heterosexual (3)	28 ( 5.8)	18 ( 4.4)	10 ( 3.1)	22 ( 7.1)	17 ( 6.7)	16 ( 6.3)
Transfusion/Hemophilia	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)
Perinatal	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)
Other/Unknown	9 ( 1.9)	6 ( 1.5)	1 ( 0.3)	6 ( 1.9)	7 ( 2.8)	19 ( 7.5)
<b>Total</b>	<b>483 ( 100)</b>	<b>409 ( 100)</b>	<b>326 ( 100)</b>	<b>310 ( 100)</b>	<b>253 ( 100)</b>	<b>252 ( 100)</b>

Transmission category (2)	Year of initial HIV diagnosis					
	2018 No. (%)	2019 No. (%)	2020 No. (%)	2021 No. (%)	2022 No. (%)	2023 No. (%)
Men who have sex with men (MSM)	145 (65.9)	128 (69.9)	105 (69.1)	96 (56.1)	116 (69.5)	91 (68.9)
People who inject drugs (PWID)	26 (11.8)	11 ( 6.0)	14 ( 9.2)	18 (10.5)	12 ( 7.2)	9 ( 6.8)
MSM-PWID	29 (13.2)	21 (11.5)	15 ( 9.9)	27 (15.8)	17 (10.2)	16 (12.1)
Heterosexual (3)	12 ( 5.5)	12 ( 6.6)	8 ( 5.3)	11 ( 6.4)	9 ( 5.4)	4 ( 3.0)
Transfusion/Hemophilia	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)
Perinatal	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)
Other/Unknown	8 ( 3.6)	11 ( 6.0)	10 ( 6.6)	19 (11.1)	13 ( 7.8)	12 ( 9.1)
<b>Total</b>	<b>220 ( 100)</b>	<b>183 ( 100)</b>	<b>152 ( 100)</b>	<b>171 ( 100)</b>	<b>167 ( 100)</b>	<b>132 ( 100)</b>

- (1) Includes persons diagnosed with HIV infection regardless of disease stage. The initial year of HIV diagnosis was determined based on the earliest date of positive HIV antibody test, positive HIV antigen/antibody combination test, detectable viral load, physician-documented diagnosis in absence of sufficient laboratory evidence, or patient self-report of a positive HIV test. Data in recent years are incomplete due to delays in case reporting.
- (2) Persons with more than one risk factor (other than the combinations listed in the tables) are tabulated only in the most likely transmission category.
- (3) Includes persons who have had heterosexual contact with a person with HIV or with a person who is at risk for HIV.

## HIV Semi-Annual Surveillance Report Cases Diagnosed as of 12/31/2023 and Reported as of 03/02/2024

**Table 8. Diagnoses of HIV infection stage 3 (AIDS) by transmission category and year of AIDS diagnosis (1), San Francisco, 2012-2023**

Transmission category (2)	Year of AIDS diagnosis					
	2012 No. (%)	2013 No. (%)	2014 No. (%)	2015 No. (%)	2016 No. (%)	2017 No. (%)
Men who have sex with men (MSM)	152 (62.6)	111 (59.4)	95 (68.3)	72 (57.6)	58 (59.8)	64 (48.5)
People who inject drugs (PWID)	23 ( 9.5)	19 (10.2)	16 (11.5)	19 (15.2)	12 (12.4)	14 (10.6)
MSM-PWID	42 (17.3)	44 (23.5)	21 (15.1)	23 (18.4)	16 (16.5)	29 (22.0)
Heterosexual (3)	21 ( 8.6)	12 ( 6.4)	7 ( 5.0)	10 ( 8.0)	11 (11.3)	19 (14.4)
Transfusion/Hemophilia	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)
Perinatal	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)
Other/Unknown	5 ( 2.1)	1 ( 0.5)	0 ( 0.0)	1 ( 0.8)	0 ( 0.0)	6 ( 4.5)
<b>Total</b>	<b>243 ( 100)</b>	<b>187 ( 100)</b>	<b>139 ( 100)</b>	<b>125 ( 100)</b>	<b>97 ( 100)</b>	<b>132 ( 100)</b>

Transmission category (2)	Year of AIDS diagnosis					
	2018 No. (%)	2019 No. (%)	2020 No. (%)	2021 No. (%)	2022 No. (%)	2023 No. (%)
Men who have sex with men (MSM)	67 (58.3)	63 (56.8)	45 (51.1)	37 (41.6)	40 (55.6)	66 (71.7)
People who inject drugs (PWID)	14 (12.2)	12 (10.8)	6 ( 6.8)	20 (22.5)	11 (15.3)	8 ( 8.7)
MSM-PWID	22 (19.1)	28 (25.2)	27 (30.7)	19 (21.3)	14 (19.4)	13 (14.1)
Heterosexual (3)	8 ( 7.0)	6 ( 5.4)	4 ( 4.5)	7 ( 7.9)	3 ( 4.2)	2 ( 2.2)
Transfusion/Hemophilia	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)
Perinatal	0 ( 0.0)	0 ( 0.0)	0 ( 0.0)	1 ( 1.1)	0 ( 0.0)	0 ( 0.0)
Other/Unknown	4 ( 3.5)	2 ( 1.8)	6 ( 6.8)	5 ( 5.6)	4 ( 5.6)	3 ( 3.3)
<b>Total</b>	<b>115 ( 100)</b>	<b>111 ( 100)</b>	<b>88 ( 100)</b>	<b>89 ( 100)</b>	<b>72 ( 100)</b>	<b>92 ( 100)</b>

(1) Data in recent years are incomplete due to delays in case reporting.

(2) Persons with more than one risk factor (other than the combinations listed in the tables) are tabulated only in the most likely transmission category.

(3) Includes persons who have had heterosexual contact with a person with HIV or with a person who is at risk for HIV.

**HIV Semi-Annual Surveillance Report  
Cases Diagnosed as of 12/31/2023 and  
Reported as of 03/02/2024**

Table 9. Diagnoses of HIV infection, HIV deaths and persons living with HIV as of 12/31/2023 by year, San Francisco, 2002-2023

Year	Number of cases diagnosed per year (1)	Number of deaths occurred per year (1)	Number of persons living with HIV infection (1)
2002 (2)	653	347	13314
2003	638	329	13623
2004	693	335	13981
2005	557	342	14196
2006	542	325	14413
2007	535	323	14625
2008	529	264	14890
2009	478	249	15119
2010	479	244	15354
2011	436	236	15554
2012	483	235	15802
2013	409	258	15953
2014	326	239	16040
2015	310	256	16094
2016	253	234	16113
2017	252	253	16112
2018	220	257	16075
2019	183	263	15995
2020	152	288	15859
2021	171	277	15753
2022	167	318	15602
2023	132	191	15543

(1) Data in recent years are incomplete due to delays in case/death reporting.

(2) Year of the mandatory reporting of HIV non-AIDS cases in California began.

**HIV Semi-Annual Surveillance Report**  
**Cases Diagnosed as of 12/31/2023 and**  
**Reported as of 03/02/2024**

Table 10. Diagnoses of HIV infection stage 3 (AIDS), AIDS deaths and persons living with AIDS as of 12/31/2023 by year, San Francisco, 1980-2023

Year	Number of cases diagnosed per year (1)	Number of deaths occurred per year (1)	Number of persons living with AIDS (1)
1980	3	0	3
1981	26	8	21
1982	99	32	88
1983	274	111	251
1984	557	273	535
1985	859	534	860
1986	1236	807	1289
1987	1636	878	2047
1988	1762	1038	2771
1989	2159	1278	3652
1990	2043	1364	4331
1991	2284	1512	5103
1992	2323	1639	5787
1993	2061	1603	6245
1994	1774	1600	6419
1995	1546	1486	6479
1996	1061	992	6548
1997	792	424	6916
1998	681	401	7196
1999	572	352	7416
2000	552	349	7619
2001	505	324	7800
2002	478	320	7958
2003	542	293	8207
2004	476	300	8383
2005	475	307	8551
2006	450	287	8714
2007	443	269	8888
2008	434	227	9095
2009	325	207	9213
2010	301	193	9321
2011	252	190	9383
2012	243	181	9445
2013	187	191	9441
2014	139	188	9392
2015	125	203	9314
2016	97	183	9228
2017	132	202	9158
2018	115	208	9065
2019	111	192	8984
2020	88	209	8863
2021	89	203	8749
2022	72	247	8574
2023	92	148	8518
Total	30471	21953	

(1) Data in recent years are incomplete due to delays in case/death reporting.

**HIV Semi-Annual Surveillance Report  
Cases Diagnosed as of 12/31/2023 and  
Reported as of 03/02/2024**

**Table 11. Persons living with HIV infection as of 12/31/2023 by age, gender and race/ethnicity, San Francisco**

Current age (1) (years) (%)	White		Black/African American		Latinx		Asian/ Pacific Islander/ Native American		Multiple races		Total No.	
	No.	(%)	No.	(%)	No.	(%)	No.	(%)	No.	(%)		
<b>Cis Men</b>												
0 - 12	0	( 0.0)	0	( 0.0)	0	( 0.0)	0	( 0.0)	0	( 0.0)	0	( 0.0)
13 - 17	0	( 0.0)	0	( 0.0)	0	( 0.0)	0	( 0.0)	0	( 0.0)	0	( 0.0)
18 - 24	4	( 0.0)	10	( 0.8)	29	( 1.0)	6	( 0.6)	1	( 0.2)	50	( 0.4)
25 - 29	34	( 0.4)	31	( 2.3)	75	( 2.5)	21	( 2.1)	5	( 1.0)	166	( 1.2)
30 - 39	392	( 4.7)	153	(11.6)	493	(16.2)	165	(16.7)	40	( 8.1)	1243	( 8.8)
40 - 49	899	(10.8)	167	(12.6)	620	(20.4)	232	(23.4)	106	(21.4)	2025	(14.3)
50 - 59	2447	(29.3)	345	(26.1)	926	(30.4)	326	(32.9)	161	(32.5)	4207	(29.6)
60 +	4575	(54.8)	615	(46.6)	899	(29.6)	240	(24.2)	182	(36.8)	6514	(45.9)
<b>Cis Men Total</b>	<b>8351</b>	<b>( 100)</b>	<b>1321</b>	<b>( 100)</b>	<b>3042</b>	<b>( 100)</b>	<b>990</b>	<b>( 100)</b>	<b>495</b>	<b>( 100)</b>	<b>14205</b>	<b>( 100)</b>
<b>Cis Women</b>												
0 - 12	0	( 0.0)	0	( 0.0)	0	( 0.0)	0	( 0.0)	0	( 0.0)	0	( 0.0)
13 - 17	0	( 0.0)	0	( 0.0)	0	( 0.0)	0	( 0.0)	0	( 0.0)	0	( 0.0)
18 - 24	0	( 0.0)	2	( 0.6)	2	( 0.9)	0	( 0.0)	1	( 2.8)	5	( 0.6)
25 - 29	1	( 0.4)	9	( 2.9)	12	( 5.5)	2	( 2.4)	5	(13.9)	29	( 3.3)
30 - 39	23	( 9.9)	25	( 8.0)	32	(14.6)	7	( 8.3)	2	( 5.6)	89	(10.0)
40 - 49	37	(15.9)	54	(17.2)	45	(20.5)	23	(27.4)	10	(27.8)	170	(19.1)
50 - 59	71	(30.5)	79	(25.2)	54	(24.7)	26	(31.0)	11	(30.6)	241	(27.1)
60 +	101	(43.3)	145	(46.2)	74	(33.8)	26	(31.0)	7	(19.4)	354	(39.9)
<b>Cis Women Total</b>	<b>233</b>	<b>( 100)</b>	<b>314</b>	<b>( 100)</b>	<b>219</b>	<b>( 100)</b>	<b>84</b>	<b>( 100)</b>	<b>36</b>	<b>( 100)</b>	<b>888</b>	<b>( 100)</b>
<b>Trans Women Total</b>	<b>71</b>	<b>( 100)</b>	<b>127</b>	<b>( 100)</b>	<b>161</b>	<b>( 100)</b>	<b>53</b>	<b>( 100)</b>	<b>26</b>	<b>( 100)</b>	<b>438</b>	<b>( 100)</b>

(1) Total includes persons with unknown race. Data on trans men are not released separately due to small numbers.

## HIV Semi-Annual Surveillance Report Cases Diagnosed as of 12/31/2023 and Reported as of 03/02/2024

Table 12. Persons living with HIV infection as of 12/31/2023 by transmission category, gender and race/ethnicity, San Francisco

Transmission category (1)	White No. (%)	Black/ African American No. (%)	Latinx No. (%)	Asian/Pacific Islander/ Native American No. (%)	Multiple races No. (%)	Total (2) No. (%)
<b>Cis Men</b>						
Men who have sex with men (MSM)	6879 (82.4)	842 (63.7)	2525 (83.0)	846 (85.5)	357 (72.1)	11450 (80.6)
People who inject drugs (PWID)	154 ( 1.8)	148 (11.2)	67 ( 2.2)	24 ( 2.4)	18 ( 3.6)	411 ( 2.9)
MSM-IDU	1235 (14.8)	230 (17.4)	343 (11.3)	81 ( 8.2)	109 (22.0)	1998 (14.1)
Heterosexual (3)	30 ( 0.4)	61 ( 4.6)	54 ( 1.8)	19 ( 1.9)	6 ( 1.9)	170 ( 1.2)
Transfusion/Hemophiliac	5 ( 0.1)	1 ( 0.1)	2 ( 0.1)	3 ( 0.3)	0 ( 0.0)	11 ( 0.1)
Perinatal	1 ( 0.0)	3 ( 0.2)	2 ( 0.1)	1 ( 0.1)	2 ( 0.4)	9 ( 0.1)
Other/Unknown	47 ( 0.6)	36 ( 2.7)	49 ( 1.6)	16 ( 1.6)	3 ( 0.6)	156 ( 1.1)
<b>Cis Men Total</b>	<b>8351 ( 100)</b>	<b>1321 ( 100)</b>	<b>3042 ( 100)</b>	<b>990 ( 100)</b>	<b>495 ( 100)</b>	<b>14205 ( 100)</b>
<b>Cis Women</b>						
People who inject drugs (PWID)	127 (54.5)	142 (45.2)	60 (27.4)	12 (14.3)	17 (47.2)	358 (40.3)
Heterosexual (3)	79 (33.9)	136 (43.3)	118 (53.9)	59 (70.2)	10 (27.8)	402 (45.3)
Transfusion/Hemophilia	5 ( 2.1)	0 ( 0.0)	2 ( 0.9)	2 ( 2.4)	0 ( 0.0)	9 ( 1.0)
Perinatal	0 ( 0.0)	6 ( 1.9)	9 ( 4.1)	0 ( 0.0)	3 ( 8.3)	18 ( 2.0)
Other/Unknown	22 ( 9.4)	30 ( 9.6)	30 (13.7)	11 (13.1)	6 (16.7)	101 (11.4)
<b>Cis Women Total</b>	<b>233 ( 100)</b>	<b>314 ( 100)</b>	<b>219 ( 100)</b>	<b>84 ( 100)</b>	<b>36 ( 100)</b>	<b>888 ( 100)</b>
<b>Trans Women Total</b>	<b>71 ( 100)</b>	<b>127 ( 100)</b>	<b>161 ( 100)</b>	<b>53 ( 100)</b>	<b>26 ( 100)</b>	<b>438 ( 100)</b>

(1) Persons with more than one risk factor (other than the combinations listed in the tables) are tabulated only in the most likely transmission category.

(2) Total includes persons with unknown race. Data on trans men are not released separately due to small numbers.

(3) Includes persons who have had heterosexual contact with a person with HIV or with a person who is at risk for HIV.